Drug Search Results
More Filters [+]

Selpercatinib

Alternative Names: selpercatinib, retevmo, loxo-292, loxo292, loxo 292, ly-3527723, ly3527723, ly 3527723
Latest Update: 2024-07-11
Latest Update Note: Clinical Trial Update

Product Description

Selpercatinib (formerly known as LOXO-292) is a novel, ATP-competitive, highly selective, small-molecule RET kinase inhibitor.

Mechanisms of Action: RET Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Bangladesh | Belgium | Canada | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Spain | Sweden | Switzerland | Taiwan | United Arab Emirates | United Kingdom | United States

Approved Indications: Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Small Cell Lung Cancer | Thyroid Cancer | Oncology Unspecified

Known Adverse Events: Hypertension | Mouth Abnormalities | Constipation | Diarrhea | Edema

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Selpercatinib

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Greece, Hong Kong, India, Israel, Italy, Japan, Korea, Mexico, Netherlands, Norway, Poland, Puerto Rico, Romania, Russia, Singapore, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 32

Highest Development Phases

Phase 3: Medullary Carcinoma|Neuroendocrine Carcinoma|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Thyroid Cancer

Phase 2: Abnormalities, Multiple|Brain Stem Cancer|Central Nervous System Cancer|Colonic Diseases|Colorectal Cancer|Fibrosarcoma|Follicular Adenocarcinoma|Hodgkin Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Multiple Myeloma|Myofibromatosis|Oncology Solid Tumor Unspecified|Oncology Unspecified|Papillary Adenocarcinoma|Papillary Carcinoma|Papillary Follicular Carcinoma|Soft Tissue Cancer|Vision, Low

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LIBRETTO-432

P3

Active, not recruiting

Non-Small-Cell Lung Cancer|Small Cell Lung Cancer

2033-03-22

J2G-MC-JZJX

P3

Not yet recruiting

Small Cell Lung Cancer|Non-Small-Cell Lung Cancer

2032-08-14

RAISE

P2

Not yet recruiting

Thyroid Cancer

2030-08-01

LOXO-RET-17001

P2

Active, not recruiting

Thyroid Cancer

2028-05-31

Recent News Events